knowledge -WSS

knowledge

author：Wikipedia 2025-09-03 15:21:24 - browse：6713

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Unicorn down: Following layoffs, Biofourmis CEO quietly departs

focus

WSS

The most pressing bird flu mysteries scientists want answered

FDA panel gives mixed vote on blood pressure devices

Illumina board agrees to spin off Grail, as divestment plans proceed

Structure Therapeutics oral GLP

Study finds new variant for Parkinson’s in African populations

What AAP's gender

hotspot

knowledge

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Congress needs to close a vaccine

Medical leaders decry Supreme Court decision on affirmative action

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

In Memoriam: Notable people who died in 2023

Psilocybin's anti

Cancer drug shortages should be causing more outrage

Why more medical students aren't specializing in primary care

Psychedelics group wrestles with new pharma identity

The most pressing bird flu mysteries scientists want answered

entertainment

In science, is the line between industry and academia shifting?

Senators tussle over abortion against the backdrop of a presidential campaign

Sutter Health’s antitrust win overturned by appeals court

As pharma fights Medicare drug negotiation, hospitals, docs silent

How a symptom of dementia informs our understanding of creativity

How CO2 helps viruses stay alive longer in the air

hotspot

focus

hotspot

hotspot